Key result
Initiating antiarrhythmic drugs in patients with the lowest baseline AF burden resulted in a greater relative reduction of AF burden compared to higher burden groups.
Why the study?
Although CIEDs can measure AF early, the optimal timing for administering antiarrhythmic drugs to suppress AF remains unclear.
Does baseline AF burden affect the relative reduction of AF burden and maximum AF duration after starting antiarrhythmic drugs in patients with nonpermanent AF?
Cohort (n=145)
Yes
Does baseline AF burden affect the relative reduction of AF burden and maximum AF duration after starting antiarrhythmic drugs in patients with nonpermanent AF?
Lower baseline AF burden is associated with a greater relative reduction in AF burden following antiarrhythmic drug initiation, suggesting early rhythm control may yield better responses.
Answers are grounded in this paper and cite their sources.
May favor early antiarrhythmic use in low-burden AF; hypothesis-generating and requires RCT confirmation before practice change.
INTRODUCTION: Cardiac implantable electronic devices (CIEDs) can measure atrial fibrillation (AF) early; however, the timing for administering antiarrhythmic drugs (AADs) to suppress AF remains unclear. This study aimed to investigate the association between baseline values and changes after AAD in terms of relative reduction of AF burden (RRAB) and maximum AF duration (RRMD). METHODS: This multicenter retrospective study screened all patients with nonpermanent AF who had dual-chamber pacemakers and only enrolled those receiving a naive AAD between September 2009 and December 2014. AF burden and maximum duration were calculated using CIED at 0 and 3 to 6 months after starting rhythm control. All the enrolled patients were divided into four groups according to baseline AF burden. RRAB and RRMD were monitored using CIEDs. RESULTS: Overall, 145 eligible subjects received a naive AAD for nonpermanent AF. The mean RRAB in the four groups (AF burden <1%, 1%-4%, 4%-18%, and ≥18%) were -65.3%, -46.4%, -34.7%, and -27.9% (P = 0.005), respectively. Mean RRMD were -26.8%, -12.4%, 4.2%, and 6.0%, respectively ( P = 0.006). Multivariate analysis revealed that the lowest baseline AF burden (<1%) was significantly associated with greater RRAB, which was not observed in the RRMD model. CONCLUSIONS: Lower baseline AF burden was associated with greater RRAB by AADs. Our finding suggests that rhythm control should be started in the early stage to achieve better responses to AADs.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2018) conducted a cohort in Nonpermanent atrial fibrillation (n=145). Antiarrhythmic drugs (AADs) vs. Different baseline AF burden groups (<1%, 1%-4%, 4%-18%, and ≥18%) was evaluated on Relative reduction of AF burden (RRAB) (p=0.005). Initiating antiarrhythmic drugs in patients with the lowest baseline AF burden (<1%) resulted in a significantly greater relative reduction of AF burden (-65.3%) compared to higher burden groups (P=0.005).
Synapse has enriched 10 related papers. Consider them for comparative context: